We thank the participants of the study.
F. Hoffmann-La Roche Ltd. supported and contributed to all aspects of the study, including the study design; financial support to Edelman for assistance with conducting the study; Endpoint Outcomes for assistance with analyses, data interpretation, and report writing; and funding of publication fees. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Support for third-party writing assistance for this manuscript, provided by Joanne Vaughan, B.Sc., of Envision Pharma Group, was provided by F. Hoffmann-La Roche Ltd.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
SS, EAT, RHG, AK, IJS, AJ, PL, and DF contributed to the conception and design of the study and the analysis and interpretation of data, drafted the article or revised it critically for important intellectual content, and approved the final version to be published.
Sobha Sivaprasad is a consultant for and reports financial support from Allergan, Bayer, Novartis, Optos, Heidelberg Engineering, and Boehringer Ingelheim; and reports financial support from Roche. Elizabeth A. Tschosik is an employee of Genentech, Inc., and reports stock/stock options from Roche. Audrey Kapre is an employee of Genentech, Inc., and reports stock/stock options from Roche. Daniela Ferrara is an employee of Genentech, Inc., and reports stock/stock options from Roche. Robyn H. Guymer is a consultant for Bayer, Genentech, Inc., Novartis, and Roche. Ivan J. Suñer is a consultant for Alimera, Allergan, Genentech, Inc., Notal Vision, and Regeneron; reports financial support from Genentech, Inc., Notal Vision, and Regeneron; and reports research funding from Genentech, Inc and Alimera. Antonia M. Joussen is a consultant for Allergan, Bayer, Novartis, and Roche, and reports financial support from Bayer. Paolo Lanzetta is a consultant for Alcon, Alimera, Allergan, Bausch + Lomb, Bayer, Boehringer Ingelheim, CenterVue, Genentech, Inc., Iridex, Lupin, Lutronic, Novartis, Roche, Teva, and Topcon.
Compliance with Ethics Guidelines
The study was approved by independent review/ethics boards for conduct in the United States, Germany, and the United Kingdom, prior to the recruitment of subjects. The study was conducted according to the Declaration of Helsinki. Written informed consent was obtained from all subjects (with assistance from caregivers if needed due to difficulty with reading) prior to the start of the interviews.
Data sharing is not applicable to this article as the data described in this study are derived from the analysis of videos with patient interviews in their native language and their transcripts by coding.
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.